bcl-2 protein expression is associated with a prognostically favourable phenotype in breast cancer irrespective of p53 immunostaining

被引:27
作者
Nakopoulou, L
Michalopoulou, A
Giannopoulou, I
Tzonou, A
Keramopoulos, A
Lazaris, AC
Davaris, PS
机构
[1] Univ Athens, Dept Pathol, Fac Med, GR-11527 Athens, Greece
[2] Univ Athens, Dept Epidemiol, Fac Med, GR-11527 Athens, Greece
[3] Univ Athens, Dept Obstet & Gynaecol, Fac Med, GR-11527 Athens, Greece
关键词
bcl-2; breast cancer; human; immunohistochemistry; p53;
D O I
10.1046/j.1365-2559.1999.00627.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aim: A role for altered programmed cell death in cancer stems from the description of alterations on tumour-associated genes involved in the regulation of apoptosis such as p53 and bcl-2, The balance between the latter may have significant implications for the pathobiology of breast cancer. This study was therefore undertaken to evaluate the expression of these two gene products with opposite functions. Methods nod results: A total of 142 paraffin-embedded tumour blocks were evaluated for nuclear p53 (a marker of p53 inactivation) and cytoplasmic bcl-2 immunohistochemistry. The results were semiquantitated, The bcl-2 protein was found within the infiltrating neoplastic cells of 97 (68%) specimens but it was also detectable in tumours' in situ compartments and in benign mammary tissue. We identified a strong correlation between bcl-2 immunoreactivity and oestrogen receptor positivity (P=0.03), while bcl-2 expression also correlated significantly with small tumour size (P=0.006) and low nuclear grade (P=0.01), but it did not correlate with the expression of p53, bcl-2 presence tended to diminish with disease progression (P=0.06). Quantitatively increased bcl-2 immunostaining was significantly associated with older patients (P=0.02) as well as with presence of progesterone receptors (P=0.01), Thirty-seven tumours (26%) were judged positive for p53 protein expression. The p53 positivity status was independent of all classical histopathological variables; however, high p53 expression was negatively linked to oestrogen receptors (P=0.005), Conclusion: In breast cancer, bcl-2 protein is associated with a prognostically favourable phenotype and appears to be related to hormonal regulation, rather than to disabled p53 gene function.
引用
收藏
页码:310 / 319
页数:10
相关论文
共 39 条
[21]   Tumour grade does not change between primary and recurrent mammary carcinoma [J].
Millis, RR ;
Barnes, DM ;
Lampejo, OT ;
Egan, MK ;
Smith, P .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (04) :548-553
[22]  
Nakopoulou LL, 1996, J PATHOL, V179, P31, DOI 10.1002/(SICI)1096-9896(199605)179:1<31::AID-PATH523>3.0.CO
[23]  
2-O
[24]  
Olopade OI, 1997, CANCER J SCI AM, V3, P230
[25]   The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer [J].
OMalley, FP ;
Saad, Z ;
Kerkvliet, N ;
Doig, G ;
Stitt, L ;
Ainsworth, P ;
Hundal, H ;
Chambers, AF ;
Turnbull, DI ;
Bramwell, V .
HUMAN PATHOLOGY, 1996, 27 (09) :955-963
[26]   HISTOLOGICAL GRADING OF BREAST CARCINOMAS - A STUDY OF INTEROBSERVER AGREEMENT [J].
ROBBINS, P ;
PINDER, S ;
DEKLERK, N ;
DAWKINS, H ;
HARVEY, J ;
STERRETT, G ;
ELLIS, I ;
ELSTON, C .
HUMAN PATHOLOGY, 1995, 26 (08) :873-879
[27]   p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients [J].
Silvestrini, R ;
Benini, E ;
Veneroni, S ;
Daidone, MG ;
Tomasic, G ;
Squicciarini, P ;
Salvadori, B .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) :1604-1610
[28]  
Siziopikou KP, 1996, CANCER, V77, P499, DOI 10.1002/(SICI)1097-0142(19960201)77:3<499::AID-CNCR11>3.0.CO
[29]  
2-#
[30]  
UPADHYAY S, 1995, CANCER RES, V55, P4520